A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Improve ADHD Product...
Second Consecutive Quarter of Positive Adjusted EBITDAQuarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx SegmentCompany to Host Conference Call Today at 5:00pm ETENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu")...
ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
ENGLEWOOD, CO / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the...
ENGLEWOOD, CO / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
ENGLEWOOD, CO / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
ENGLEWOOD, CO / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
Aytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply DisruptionENGLEWOOD, CO / January 10, 2023 / Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them...
ENGLEWOOD, CO / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a...
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply DisruptionAdzenys XR-ODT is the Only...